01 / 20

Chronic Kidney
Disease Management

Staging by eGFR and albuminuria, slowing progression, and treating complications of declining renal function.

USMLE Step 3

What Is CKD?

Chronic kidney disease is defined as abnormalities of kidney structure or function present for at least 3 months, with implications for health. The key markers are a reduced filtration rate and persistent kidney damage.

Two Key Measurements

eGFR
Estimated glomerular filtration rate, in \( \text{mL/min/1.73 m}^2 \). Reflects how well the kidneys filter blood.
Albuminuria
Urine albumin-to-creatinine ratio (UACR) in \( \text{mg/g} \). Reflects kidney damage and predicts progression.

Estimating eGFR

eGFR is estimated from serum creatinine using equations like CKD-EPI. Conceptually, filtration is inversely related to creatinine:

eGFR Creatinine Low Cr, high eGFR High Cr, low eGFR

GFR Staging (G1–G5)

G1 eGFR \( \geq 90 \) — normal G2 eGFR 60–89 — mild G3a/b eGFR 30–59 — moderate G4 eGFR 15–29 — severe G5 eGFR \( < 15 \) — kidney failure

The KDIGO Risk Grid

Risk of CKD progression is determined by combining G stage (eGFR) with A stage (albuminuria). Higher numbers on either axis push the patient into a higher-risk zone.

Albuminuria (A1 → A3) eGFR (G1 → G5) G1 G2 G3 G4 G5 A1 A2 A3

Albuminuria Categories

A1
UACR \( < 30\,\text{mg/g} \). Normal to mildly increased.
A2
UACR 30–300 \( \text{mg/g} \). Moderately increased (formerly "microalbuminuria").
A3
UACR \( > 300\,\text{mg/g} \). Severely increased.

AKI vs. CKD

Acute Kidney Injury Chronic Kidney Disease
TimeframeHours to days\( \geq 3 \) months
Kidney sizeUsually normalOften small / echogenic
AnemiaTypically absentCommon (low EPO)
ReversibilityOften reversibleUsually progressive

A Stepwise Approach

1
Confirm and stage. Repeat eGFR and UACR over 3 months; assign G and A stages.
2
Control BP and proteinuria. Start an ACEi or ARB; target BP \( < 130/80 \).
3
Manage diabetes. Add an SGLT2 inhibitor for cardiorenal protection.
4
Treat complications. Anemia, mineral-bone disease, acidosis, hyperkalemia.
5
Refer and plan. Nephrology referral and dialysis/transplant planning in advanced CKD.

Slowing Progression

RAAS Blockade
ACEi/ARB reduce intraglomerular pressure and albuminuria. Expect a small early Cr rise (up to \( \approx 30\% \)).
SGLT2 Inhibitors
Slow eGFR decline in diabetic and non-diabetic CKD; offer cardiorenal benefit.
BP & Glucose
Tight control of blood pressure and glycemia protects nephrons over time.

Example 1: Staging

1
eGFR 45 falls in 30–59 → G3a.
2
UACR 200 falls in 30–300 → A2.
3
Diagnosis: CKD stage G3aA2 — high-risk zone.

Example 2: Hyperkalemia

1
Stabilize the myocardium first: IV calcium gluconate.
2
Shift K⁺ intracellularly: insulin + glucose, \( \beta \)-agonist.
3
Remove K⁺: binders (patiromer), loop diuretic, dialysis if refractory.

Example 3: Anemia of CKD

1
Confirm iron studies first. Replete iron before considering ESAs.
2
Anemia is from decreased erythropoietin production by failing kidneys.
3
If iron-replete and symptomatic, add an ESA, targeting Hgb \( 10\text{–}11\,\text{g/dL} \).

Common Mistakes

✕ Stopping ACEi for small Cr rise
A rise up to \( \approx 30\% \) is expected and acceptable; continue the drug.
✕ Diagnosing CKD on one value
Chronicity requires markers persisting \( \geq 3 \) months.
✕ Ignoring albuminuria
Normal eGFR with heavy proteinuria is still CKD.
✕ ESA before iron repletion
Always correct iron deficiency before starting an ESA.

Complications Summary

Problem Mechanism Management
AnemiaLow EPOIron, then ESA
Bone diseaseLow vit D, high \( \text{PO}_4 \), high PTHPhosphate binders, vit D
AcidosisLow acid excretionSodium bicarbonate
HyperkalemiaReduced K⁺ excretionDiet, binders, diuretics
Volume overloadSodium retentionLoop diuretics, salt restriction

Question 1 of 5

A patient has a stable eGFR of 70 but a UACR of 350 mg/g confirmed over 4 months. How should this be classified?

Question 2 of 5

A diabetic with CKD and albuminuria is started on an ACEi. Two weeks later creatinine rises 22% and \( \text{K}^+ \) is 5.0. What is the best next step?

Question 3 of 5

A type 2 diabetic with CKD G3aA2 is already on a maximally tolerated ACEi. Which agent best slows further progression and adds cardiorenal benefit?

Question 4 of 5

A CKD G4 patient has \( \text{Hgb} = 9.0\,\text{g/dL} \), normal MCV, and fatigue. What should be done before starting an erythropoiesis-stimulating agent?

Question 5 of 5

A CKD G4 patient on an ACEi presents with \( \text{K}^+ = 6.2 \) and peaked T waves. What is the first intervention?